A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain

Edward C. Halperin, James Herndon, S. Clifford Schold, Mark Brown, Nicholas Vick, J. Gregory Cairncross, David R. Macdonald, Laurie Gaspar, Barbara Fischer, Edward Dropcho, Steven Rosenfeld, Richard Morowitz, Joseph Piepmeier, William Hait, Thomas Byrne, Merle Salter, Joseph Imperato, Janardan Khandekar, Nina Paleologos, Peter Burger & 2 others Gunilla C. Bentel, Allan Friedman

Research output: Contribution to journalArticle

Abstract

Purpose: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were ≥ 15 years of age, had a histologic diagnosis of malignant glioma, and a Karnofsky performance status (KIPS) ≥ 60%. Methods and Materials: In Randomization 1, patients were assigned to receive either ERT alone (61.2 Gy) or ERT plus mitomycin C (Mito, IV 12.5 mg/m2) during the first and fourth week of ERT. After this treatment, patients went on to Randomization 2, where they were assigned to receive either BCNU (i.v. 200 mg/m2) given at 6-week intervals or 6- mercaptopurine (6-MP, 750 mg/m2 IV daily for 3 days every 6 weeks), with BCNU given on the third day of the 6-MP treatment. Three hundred twenty- seven patients underwent Randomization 1. One hundred sixty-four received ERT alone, and 163 received ERT + Mito [average age 52.7 years; 63% male; 69% glioblastoma multiforme (GBM); 66% had a resection; 56% KPS ≥ 90%]. Step- wise analysis of survival from Randomization 1 or 2 indicates that survival was significantly diminished by: (a) age ≥ 45 years (b) KIPS <90%; (c) GBM/Gliosarcoma histology; (d) stereotactic biopsy as opposed to open biopsy or resection. Median survival from Randomization 1 in both arms (ERT + Mito) was 10.8 months. Median survival from Randomization 2 was 93 months for BCNU/6MP vs. 11.4 months for the BCNU group (p = 0.35). Carmustine/6-MP showed a possible survival benefit for histologies other than GBM/GS. Two hundred and thirty-three patients underwent Randomization 2. The proportion of patients in the ERT group who terminated study prior to Randomization 2 was significantly less in the ERT group than in the ERT + Mito group (20 vs. 37%, p <0.001). Conclusions: (a) The addition of Mito to ERT had no impact on survival; (b) patients treated with ERT + Mito were at greater risk of terminating therapy prior to Randomization 2; (c) there was not a significant survival benefit in the addition of 6-MP to BCNU.

Original languageEnglish (US)
Pages (from-to)793-802
Number of pages10
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume34
Issue number4
DOIs
StatePublished - Mar 1 1996

Fingerprint

Carmustine
6-Mercaptopurine
Mitomycin
Glioma
brain
radiation therapy
Radiotherapy
Random Allocation
Brain
Survival
Therapeutics
Glioblastoma
histology
Histology
Gliosarcoma
Biopsy
Karnofsky Performance Status
Survival Analysis
stopping
therapy

Keywords

  • 6- Mercaptopurine
  • BCNU
  • Brain neoplasms
  • Carmustine
  • Chemotherapy
  • CNS neoplasms
  • Gliomas
  • Mitomycin C
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. / Halperin, Edward C.; Herndon, James; Schold, S. Clifford; Brown, Mark; Vick, Nicholas; Cairncross, J. Gregory; Macdonald, David R.; Gaspar, Laurie; Fischer, Barbara; Dropcho, Edward; Rosenfeld, Steven; Morowitz, Richard; Piepmeier, Joseph; Hait, William; Byrne, Thomas; Salter, Merle; Imperato, Joseph; Khandekar, Janardan; Paleologos, Nina; Burger, Peter; Bentel, Gunilla C.; Friedman, Allan.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 34, No. 4, 01.03.1996, p. 793-802.

Research output: Contribution to journalArticle

Halperin, EC, Herndon, J, Schold, SC, Brown, M, Vick, N, Cairncross, JG, Macdonald, DR, Gaspar, L, Fischer, B, Dropcho, E, Rosenfeld, S, Morowitz, R, Piepmeier, J, Hait, W, Byrne, T, Salter, M, Imperato, J, Khandekar, J, Paleologos, N, Burger, P, Bentel, GC & Friedman, A 1996, 'A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain', International Journal of Radiation Oncology, Biology, Physics, vol. 34, no. 4, pp. 793-802. https://doi.org/10.1016/0360-3016(95)02025-X
Halperin, Edward C. ; Herndon, James ; Schold, S. Clifford ; Brown, Mark ; Vick, Nicholas ; Cairncross, J. Gregory ; Macdonald, David R. ; Gaspar, Laurie ; Fischer, Barbara ; Dropcho, Edward ; Rosenfeld, Steven ; Morowitz, Richard ; Piepmeier, Joseph ; Hait, William ; Byrne, Thomas ; Salter, Merle ; Imperato, Joseph ; Khandekar, Janardan ; Paleologos, Nina ; Burger, Peter ; Bentel, Gunilla C. ; Friedman, Allan. / A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. In: International Journal of Radiation Oncology, Biology, Physics. 1996 ; Vol. 34, No. 4. pp. 793-802.
@article{2ced52c24ada4de7ad234920ac814713,
title = "A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain",
abstract = "Purpose: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were ≥ 15 years of age, had a histologic diagnosis of malignant glioma, and a Karnofsky performance status (KIPS) ≥ 60{\%}. Methods and Materials: In Randomization 1, patients were assigned to receive either ERT alone (61.2 Gy) or ERT plus mitomycin C (Mito, IV 12.5 mg/m2) during the first and fourth week of ERT. After this treatment, patients went on to Randomization 2, where they were assigned to receive either BCNU (i.v. 200 mg/m2) given at 6-week intervals or 6- mercaptopurine (6-MP, 750 mg/m2 IV daily for 3 days every 6 weeks), with BCNU given on the third day of the 6-MP treatment. Three hundred twenty- seven patients underwent Randomization 1. One hundred sixty-four received ERT alone, and 163 received ERT + Mito [average age 52.7 years; 63{\%} male; 69{\%} glioblastoma multiforme (GBM); 66{\%} had a resection; 56{\%} KPS ≥ 90{\%}]. Step- wise analysis of survival from Randomization 1 or 2 indicates that survival was significantly diminished by: (a) age ≥ 45 years (b) KIPS <90{\%}; (c) GBM/Gliosarcoma histology; (d) stereotactic biopsy as opposed to open biopsy or resection. Median survival from Randomization 1 in both arms (ERT + Mito) was 10.8 months. Median survival from Randomization 2 was 93 months for BCNU/6MP vs. 11.4 months for the BCNU group (p = 0.35). Carmustine/6-MP showed a possible survival benefit for histologies other than GBM/GS. Two hundred and thirty-three patients underwent Randomization 2. The proportion of patients in the ERT group who terminated study prior to Randomization 2 was significantly less in the ERT group than in the ERT + Mito group (20 vs. 37{\%}, p <0.001). Conclusions: (a) The addition of Mito to ERT had no impact on survival; (b) patients treated with ERT + Mito were at greater risk of terminating therapy prior to Randomization 2; (c) there was not a significant survival benefit in the addition of 6-MP to BCNU.",
keywords = "6- Mercaptopurine, BCNU, Brain neoplasms, Carmustine, Chemotherapy, CNS neoplasms, Gliomas, Mitomycin C, Radiation therapy",
author = "Halperin, {Edward C.} and James Herndon and Schold, {S. Clifford} and Mark Brown and Nicholas Vick and Cairncross, {J. Gregory} and Macdonald, {David R.} and Laurie Gaspar and Barbara Fischer and Edward Dropcho and Steven Rosenfeld and Richard Morowitz and Joseph Piepmeier and William Hait and Thomas Byrne and Merle Salter and Joseph Imperato and Janardan Khandekar and Nina Paleologos and Peter Burger and Bentel, {Gunilla C.} and Allan Friedman",
year = "1996",
month = "3",
day = "1",
doi = "10.1016/0360-3016(95)02025-X",
language = "English (US)",
volume = "34",
pages = "793--802",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain

AU - Halperin, Edward C.

AU - Herndon, James

AU - Schold, S. Clifford

AU - Brown, Mark

AU - Vick, Nicholas

AU - Cairncross, J. Gregory

AU - Macdonald, David R.

AU - Gaspar, Laurie

AU - Fischer, Barbara

AU - Dropcho, Edward

AU - Rosenfeld, Steven

AU - Morowitz, Richard

AU - Piepmeier, Joseph

AU - Hait, William

AU - Byrne, Thomas

AU - Salter, Merle

AU - Imperato, Joseph

AU - Khandekar, Janardan

AU - Paleologos, Nina

AU - Burger, Peter

AU - Bentel, Gunilla C.

AU - Friedman, Allan

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Purpose: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were ≥ 15 years of age, had a histologic diagnosis of malignant glioma, and a Karnofsky performance status (KIPS) ≥ 60%. Methods and Materials: In Randomization 1, patients were assigned to receive either ERT alone (61.2 Gy) or ERT plus mitomycin C (Mito, IV 12.5 mg/m2) during the first and fourth week of ERT. After this treatment, patients went on to Randomization 2, where they were assigned to receive either BCNU (i.v. 200 mg/m2) given at 6-week intervals or 6- mercaptopurine (6-MP, 750 mg/m2 IV daily for 3 days every 6 weeks), with BCNU given on the third day of the 6-MP treatment. Three hundred twenty- seven patients underwent Randomization 1. One hundred sixty-four received ERT alone, and 163 received ERT + Mito [average age 52.7 years; 63% male; 69% glioblastoma multiforme (GBM); 66% had a resection; 56% KPS ≥ 90%]. Step- wise analysis of survival from Randomization 1 or 2 indicates that survival was significantly diminished by: (a) age ≥ 45 years (b) KIPS <90%; (c) GBM/Gliosarcoma histology; (d) stereotactic biopsy as opposed to open biopsy or resection. Median survival from Randomization 1 in both arms (ERT + Mito) was 10.8 months. Median survival from Randomization 2 was 93 months for BCNU/6MP vs. 11.4 months for the BCNU group (p = 0.35). Carmustine/6-MP showed a possible survival benefit for histologies other than GBM/GS. Two hundred and thirty-three patients underwent Randomization 2. The proportion of patients in the ERT group who terminated study prior to Randomization 2 was significantly less in the ERT group than in the ERT + Mito group (20 vs. 37%, p <0.001). Conclusions: (a) The addition of Mito to ERT had no impact on survival; (b) patients treated with ERT + Mito were at greater risk of terminating therapy prior to Randomization 2; (c) there was not a significant survival benefit in the addition of 6-MP to BCNU.

AB - Purpose: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were ≥ 15 years of age, had a histologic diagnosis of malignant glioma, and a Karnofsky performance status (KIPS) ≥ 60%. Methods and Materials: In Randomization 1, patients were assigned to receive either ERT alone (61.2 Gy) or ERT plus mitomycin C (Mito, IV 12.5 mg/m2) during the first and fourth week of ERT. After this treatment, patients went on to Randomization 2, where they were assigned to receive either BCNU (i.v. 200 mg/m2) given at 6-week intervals or 6- mercaptopurine (6-MP, 750 mg/m2 IV daily for 3 days every 6 weeks), with BCNU given on the third day of the 6-MP treatment. Three hundred twenty- seven patients underwent Randomization 1. One hundred sixty-four received ERT alone, and 163 received ERT + Mito [average age 52.7 years; 63% male; 69% glioblastoma multiforme (GBM); 66% had a resection; 56% KPS ≥ 90%]. Step- wise analysis of survival from Randomization 1 or 2 indicates that survival was significantly diminished by: (a) age ≥ 45 years (b) KIPS <90%; (c) GBM/Gliosarcoma histology; (d) stereotactic biopsy as opposed to open biopsy or resection. Median survival from Randomization 1 in both arms (ERT + Mito) was 10.8 months. Median survival from Randomization 2 was 93 months for BCNU/6MP vs. 11.4 months for the BCNU group (p = 0.35). Carmustine/6-MP showed a possible survival benefit for histologies other than GBM/GS. Two hundred and thirty-three patients underwent Randomization 2. The proportion of patients in the ERT group who terminated study prior to Randomization 2 was significantly less in the ERT group than in the ERT + Mito group (20 vs. 37%, p <0.001). Conclusions: (a) The addition of Mito to ERT had no impact on survival; (b) patients treated with ERT + Mito were at greater risk of terminating therapy prior to Randomization 2; (c) there was not a significant survival benefit in the addition of 6-MP to BCNU.

KW - 6- Mercaptopurine

KW - BCNU

KW - Brain neoplasms

KW - Carmustine

KW - Chemotherapy

KW - CNS neoplasms

KW - Gliomas

KW - Mitomycin C

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=9044237687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044237687&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(95)02025-X

DO - 10.1016/0360-3016(95)02025-X

M3 - Article

VL - 34

SP - 793

EP - 802

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -